News and Trends 3 Oct 2022Oncopeptides starts European commercialization of myeloma drug in Germany Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2022Knockback for drug to treat patients with relapsed or refractory multiple myeloma A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The… September 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email